SCHEMBL578063

SCHEMBL578063

Clc1nc(OCc2ccccc2)nc(OCc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 2/20 0.49
ALOX5 P09917 1/20 0.44
PTGS2 P35354 4/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
TSHR P16473 2/20 0.43
CYP1A2 P05177 2/20 0.42
LMNA P02545 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
CYP2C19 P33261 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HIF1A Q16665 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
MAPT P10636 2/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639465 0.96 PIN1 (0.49) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL32688297 0.91 MAOB (0.44) PIN1PTGS2L3MBTL1TSHRCYP1A2
SCHEMBL16086043 0.90 PIN1 (0.43) PIN1ALOX5PTGS2L3MBTL1CYP1A2
SCHEMBL11009131 0.89 TSHR (0.52) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL17066149 0.88 L3MBTL1 (0.45) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL22686879 0.84 PIN1 (0.45) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL28776503 0.83 PIN1 (0.49) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL8670167 0.82 PIN1 (0.48) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL16253511 0.80 L3MBTL1 (0.51) PIN1ALOX5PTGS2L3MBTL1TSHR
SCHEMBL17563554 0.80 MAOB (0.47) PTGS2L3MBTL1LMNAPTGS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813710-A Preparation method of carfilzomib 重庆药友制药有限责任公司 2023-09-29 CN claimed
CN-116768972-A Preparation method of carfilzomib intermediate 重庆药友制药有限责任公司 2023-09-19 CN claimed
US-8946475-B2 Processes for preparing a polymeric compound CELLCEUTIX CORPORATION (US) 2015-02-03 US claimed
EP-1912951-B1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA (DE) 2010-01-06 EP claimed
US-7608722-B2 Preparation of 1,7,′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-27 US claimed
EP-1912951-A1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-04-23 EP claimed
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-15 US claimed
WO-2007009967-A1 PREPARATION OF 1,7′-DIMETHYL-2′-PROPYL-2,5′-BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-25 WO claimed
US-20250067734-A1 Fluorescent Cellulose Particles ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-02-27 US disclosed
CN-116813710-B Preparation method of carfilzomib 重庆药友制药有限责任公司 2024-07-12 CN disclosed
CN-118119848-A Fluorescent cellulose particles 旭化成株式会社 2024-05-31 CN disclosed
US-20230310435-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT INNOVATION PHARMACEUTICALS INC. (US) 2023-10-05 US disclosed
CN-116813710-A Preparation method of carfilzomib 重庆药友制药有限责任公司 2023-09-29 CN disclosed
CN-116768972-A Preparation method of carfilzomib intermediate 重庆药友制药有限责任公司 2023-09-19 CN disclosed
US-7608722-B2 Preparation of 1,7,′-dimethyl-2′-propyl-2,5′-bi-1H-benzimidazole BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-27 US disclosed
EP-1951691-A1 PROCESS FOR THE PREPARATION OF N-TRIAZINYLAMMONIUM SALTS Italvelluti S.p.A. (IT) 2008-08-06 EP disclosed
EP-1912951-A1 PREPARATION OF 1,7` -DIMETHYL-2 `-PROPYL-2,5` -BI-1H-BENZIMIDAZOLE Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-04-23 EP disclosed
WO-2007051496-A1 PROCESS FOR THE PREPARATION OF N-TRIAZINYLAMMONIUM SALTS ITALVELLUTI S.P.A. (IT) 2007-05-10 WO disclosed
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-02-15 US disclosed
WO-2007009967-A1 PREPARATION OF 1,7′-DIMETHYL-2′-PROPYL-2,5′-BI-1H-BENZIMIDAZOLE BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037986-A1 reacting N-methyl-o-phenylenediamine with 2-propyl-4-methyl-1H-benzimidazole-6-carboxylic acid, coupling and cyclization is achieved using 1,3,5-triazine ( 2-chloro-4,6-dimethoxy-1,3,5-triazine) and tertiary amine ( morpholine, N-methyl-) PNMT, PAM, PAH PIN1 1448/4885ALOX5 1464/4885PTGS2 1105/4885
US-20230310435-A1 HOST DEFENSE PROTEIN (HDP) MIMETICS FOR PROPHYLAXIS AND/OR TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT FABP2, HMGB1, MASP2 PIN1 3129/4885ALOX5 1447/4885PTGS2 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.